Treasure Island metformin diaphium hydrochloride successfully reviewed

Medical Network May 13 hearing May 11, Treasure Island announced that a wholly owned subsidiary of Harbin Pharmaceutical Treasures received SFDA approval issued by metformin hydrochloride tablets (0.25g) "Drug Supplementary Application document," the product passed the quality and efficacy of generic drugs to evaluate the agreementIt is reported that, as of now, Treasure Island and its subsidiaries through the evaluation of two productsTreasure Island is a traditional Chinese medicine industry as the basis,industry featuring modern pharmaceutical companies, the main products include cerebrovascularproprietary heavy varieties Xuesetong, Nemi network data show that in 2019 China urban public, county public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal sales of over 2 billion yuanFIG1: Chinese public sector sales terminal Xuesetong injections (unit: million) a source: the network terminal competition m Chinese public sector
2017 version of the national medical insurance catalog on the part of traditional Chinese medicine injections limit the scope of use, which also involves Xuesetong recent years, the variety injection of negative growth in China terminal sales in public medical institutionsTreasure Island mentioned Annual 2019, the company's injection Xuesetong (lyophilized) in the following two medical institutions fell significantly, the cumulative drop of 3.26 percent, but lower than the level of the overall decline2019 version of the national medical insurance catalog Xuesetong adjustment limit injection, the "limit secondary and higher medical institutions," notes "Stroke limit secondary and higher medical institutions in patients with hemiplegia or central retinal vein occlusion," is expected in the longer period time, sales of the variety is still not back to the peak value of the originalMeanwhilemedicine companies began to seek transformation, Treasure Island in 2019 continued to focus on the kinds of research and development to promote, also vigorously promote Kayaku generic drugs and innovative drug research, production and process of listingUp to now, Treasure Island and its subsidiaries have two product consistency through the evaluation of the company's expansion into medicine, bio-medicine field positive stepTable 1: Treasure Island and its subsidiaries through a Source Product Review: m Chinese Drug Evaluation MED network database within 2.0 metersnetwork data, 2019 clindamycin hydrochloride capsules sales of around 50 million yuan, had been regarded as evaluation and assessment up to 7, January 2020 second round of the National Central Purchasing, Harbin pharmaceutical treasure won the bid Shanghai, Fujian , Guangdong and other nine provinces Metformin hydrochloride tablets up to 3 billion yuan in China terminal sales in public medical institutions, deemed too over-assessment and evaluation of enterprises reached 26 Source: Company, annual reports, the network database meters